Presents Connetics, a biotechnology and pharmaceutical companies, from its founding in 1993 through the recent clinical trials of its flagship drug compound in 2000. During this time the company had experienced the failure of another compound, while successful in-licensing other pharmaceutical products that would generate immediate income. Ultimately, the pivotal trial was a failure in 2000, and CEO Tom Wiggans, the company must by this failure (the stock fell from about $ 25 to … Read More »
manage

Presents Connetics, a biotechnology and pharmaceutical companies, from its founding in 1993 through the recent clinical trials of its flagship drug compound in 2000. During this time the company had experienced the failure of another compound, while successful in-licensing other pharmaceutical products that would generate immediate income. Ultimately, the pivotal trial was a failure in 2000, and CEO Tom Wiggans, the company must by this failure (the stock went from about $ 25 to $ 5 after the results were made public) manage.
«Hide

from
Robert Chess,
Mark Leslie,
Joshua Spitzer
Source: Stanford Graduate School of Business
26 pages.
Release Date: 15, March 2006. Prod #: E200-PDF-ENG
Connetics and relaxin HBR case solution

[related_post themes="flat"]